To the best of our knowledge, we are not aware of any life insurance company that will insure someone who has been
diagnosed with myelofibrosis.
Incyte's (NASDAQ: INCY) Jakafi racked up $ 1.1 billion in sales last year as the only targeted therapy for
patients with myelofibrosis, but a majority of patients who take it eventually relapse.
A recent phase III study revealed a benefit with pacritinib for patients
with myelofibrosis and thrombocytopenia who have experienced treatment failure with previous therapies.
Dr. Nguyen's research is focused on developing novel therapy to treat myeloproliferative neoplasms, particularly for patients
with myelofibrosis and mast cell disease.